US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genfit

3.54

0.0000

Volume:- -

Turnover:- -

Market Cap:176.15M

PE:-5.51

High:3.54

Open:3.54

Low:3.54

Close:3.54

Loading ...

Overview Company News Filings

Genfit to Receive $29.9 Million Milestone Payment Under Contract With Ipsen

MT Newswires Live

Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT Releases 2024 Annual Reports, Enhancing Transparency

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Genfit Reports Positive 2024 Financial Results and Strategic Progress

Genfit SA Reports Profit and Strategic Advances in 2024

Genfit FY EPS $(0.06) Up From $(0.62) YoY, Sales $40.74M Beat $16.30M Estimate

Press Release: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

GENFIT Secures Bondholder Approval for 2025 OCEANEs Amendments

Press Release: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Analysts’ Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Kepler Capital Sticks to Its Buy Rating for Genfit (GNFTF)

GENFIT Advances 2025 OCEANEs Repurchase with Key Agreements

Press Release: GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

GENFIT Amends Terms of 2025 OCEANEs Proposal Amid Royalty Financing

Genfit (GNFTF) Gets a Buy from Kepler Capital

GENFIT Finalizes 2025 Bond Repurchase Terms Amidst Royalty Financing Deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GNFTF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNFTF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNFTF\",,,,,undefined,":{"symbol":"GNFTF","market":"US","secType":"STK","nameCN":"Genfit","latestPrice":3.54,"timestamp":1749844800000,"preClose":3.54,"halted":0,"volume":0,"delay":15,"floatShares":41846888,"shares":49758671,"eps":-0.642605,"marketStatus":"Closed","change":0,"latestTime":"06-13 16:00:00 EDT Delay","open":3.54,"high":3.54,"low":3.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.642605,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":3.54,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNFTF\",,,,,undefined,":{"symbol":"GNFTF","floatShares":41846888,"roa":"1.14%","roe":"2.20%","lyrEps":-0.642605,"shares":49758671,"dividePrice":0,"high":3.54,"amplitude":0,"preClose":3.54,"low":3.54,"week52Low":3.44,"pbRate":"2.20","psRate":"2.16","week52High":5.55,"institutionHeld":0,"latestPrice":3.54,"eps":-0.642605,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.642605,"open":3.54,"prevYearClose":3.54,"prevWeekClose":3.54,"prevMonthClose":3.54,"prevQuarterClose":3.54,"fiveDayClose":3.54,"twentyDayClose":3.54,"sixtyDayClose":3.54},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GNFTF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537626818","title":"Genfit to Receive $29.9 Million Milestone Payment Under Contract With Ipsen","url":"https://stock-news.laohu8.com/highlight/detail?id=2537626818","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537626818?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:19","pubTimestamp":1747775962,"startTime":"0","endTime":"0","summary":"Genfit  said late Tuesday it will receive a 26.5 million Euro  milestone payment from Ipsen after Iqirvo's approval of pricing and reimbursement in Italy for Primary Biliary Cholangitis.The payment milestone under the licensing and collaboration agreement with Ipsen will further support Genfit in advancing its pipeline for severe liver diseases, according to a statement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNFT","BK4139","GNFTF"],"gpt_icon":0},{"id":"2537623154","title":"Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623154","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623154?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:20","pubTimestamp":1747772425,"startTime":"0","endTime":"0","summary":"Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis. This step unlocks ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genfit-to-receive-eur-26-5m-iqirvo-milestone-payment-from-ipsen-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genfit-to-receive-eur-26-5m-iqirvo-milestone-payment-from-ipsen-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFT","GNFTF","BK4139"],"gpt_icon":0},{"id":"2533374689","title":"GENFIT to Present Latest ACLF Research at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533374689","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533374689?lang=en_us&edition=fundamental","pubTime":"2025-05-05 13:30","pubTimestamp":1746423000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 5, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver  Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community.I.PostersSix posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ACLF.ACLFPoster #1: Intraperitoneal administration of investigational drug VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosisPoster: FRI-172. Author/s: Jonel Trebicka, Arun J. Sanyal, Thierry Artzner, William Bernal, Joan Clària, Javier Fernández, Lise Lotte Gluud, Jennifer Lai, Jacqueline O’Leary, Pierre-Emmanuel Rautou, Deb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-present-latest-aclf-research-053000310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","GNFT","BK4139","APHP","PBC","KOL","USA","BK4108","CCA","GNFTF"],"gpt_icon":0},{"id":"2531795178","title":"GENFIT Releases 2024 Annual Reports, Enhancing Transparency","url":"https://stock-news.laohu8.com/highlight/detail?id=2531795178","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531795178?lang=en_us&edition=fundamental","pubTime":"2025-04-30 03:27","pubTimestamp":1745954831,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) just unveiled an announcement. On April 29, 2025, GENFIT announced the publication of its 2024 Universal Registration Documen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-releases-2024-annual-reports-enhancing-transparency?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-releases-2024-annual-reports-enhancing-transparency?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2531266914","title":"GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531266914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531266914?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:10","pubTimestamp":1745871000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , April 28, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and significant efficacy in Primary Sclerosing Cholangitis , at the European Association for the Study of the Liver  on May 10, 2025 at 11.15 CET.Pascal Prigent, CEO of GENFIT, commented: “We continue to be very pleased with Ipsen’s commitment to developing elafibranor, and the results from the ELMWOOD Phase 2 trial further reinforce our belief in elafibranor’s potential to address serious liver diseases.”ABOUT PSCPSC is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, which can lead to liver damage and eventually liver failure. The exact cause of PSC is unknown, but it is often associated with other autoimmune conditions, such as inflam","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-positive-breaking-phase-2-201000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","ELF","CCA","GGT","PBC","LU1242518857.USD","BK4139","LU1242518931.SGD","LU1559883803.SGD","BK4585","BK4183","BK4201","USA","ALT","GNFTF","PSC","LU0053671581.USD","GNFT","LU0566484027.USD","BK4599","LU1878469433.USD","LU0979878070.USD","EC"],"gpt_icon":0},{"id":"2530759942","title":"Genfit Reports Positive 2024 Financial Results and Strategic Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2530759942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530759942?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:57","pubTimestamp":1745553447,"startTime":"0","endTime":"0","summary":"Genfit ( ($GNFT) ) has released its Q4 earnings. Here is a breakdown of the information Genfit presented to its investors. Genfit is a late-stage b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-reports-positive-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-reports-positive-2024-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","GNFTF","PRGS","BK4139","LU2065732104.USD"],"gpt_icon":0},{"id":"2530494246","title":"Genfit SA Reports Profit and Strategic Advances in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2530494246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530494246?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:57","pubTimestamp":1745553438,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFTF) ) has released its Q4 earnings. Here is a breakdown of the information Genfit SA presented to its investors. Genfit SA is a la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-sa-reports-profit-and-strategic-advances-in-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-sa-reports-profit-and-strategic-advances-in-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2530983329","title":"Genfit FY EPS $(0.06) Up From $(0.62) YoY, Sales $40.74M Beat $16.30M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2530983329","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530983329?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:14","pubTimestamp":1745525692,"startTime":"0","endTime":"0","summary":"Genfit (NASDAQ:GNFT) reported quarterly losses of $(0.06) per share. This is a 90 percent increase over losses of $(0.62) per share from the same period last year.  The company reported quarterly sales of $40.74 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44995298/genfit-fy-eps-0-06-up-from-0-62-yoy-sales-40-74m-beat-16-30m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFT","GNFTF"],"gpt_icon":0},{"id":"2530196005","title":"Press Release: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2530196005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530196005?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:10","pubTimestamp":1745525400,"startTime":"0","endTime":"0","summary":"-- Cash and cash equivalents totaled EUR81.8 million as of December 31,2024. In addition, completion in early 2025 of:  a non-dilutive. royalty financing agreement for up to EUR185 million including a first. installment of EUR130 million and  the debt repurchase offer. -- Net profit of EUR1.5 million thanks to revenues amounting to EUR67.0. million for the period ended December 31, 2024, including a EUR48.7. -- In 2024, Iqirvo received marketing approval in PBC in both the United. In 2024, GENFIT and its partner Ipsen reported significant commercial and regulatory advances with Iqirvo  in the United States, Europe and the UK.Ipsen's Iqirvo received accelerated approval from the U.S. Food and Drug Administration  on June 10, 2024 as a first-in-class treatment for PBC in combination with ursodeoxycholic","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCA","BK4232","BK4022","R","IE00BFMHRM44.USD","NICE","PBC","GNFT","BK4023","BK4543","GNFTF","BK4566","BK4139"],"gpt_icon":0},{"id":"2521494099","title":"GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494099","media":"GlobeNewswire","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494099?lang=en_us&edition=fundamental","pubTime":"2025-03-21 05:10","pubTimestamp":1742505000,"startTime":"0","endTime":"0","summary":"GENFIT completes a royalty financing of up to 185 million with HCRx after unanimous OCEANE bondholder approval, triggering a 130 million upfront payment with potential for an additional 55 million upon achieving near-term milestones. Non-dilutive financing extends cash runway beyond 2027 and supports GENFIT’s R&D efforts. Financing strengthens GENFIT's ACLF pipeline development and commitment to transformative therapies. GENFIT to use 61.66 million to repurchase 1,882,891 2025 OCEANEs after exercise by certain bondholders of their put option, reducing the nominal amount of GENFIT’s convertible debt to 586 thousand. Pascal Prigent, CEO of GENFIT, commented: “We are very pleased that we have now successfully closed this transaction. It gives us financial visibility beyond 2027 and will enable us to pursue development of all the programs in our very rich pipeline. We also believe it is positive for our shareholders as we have lifted our convertible debt burden without any dilution.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-completion-non-dilutive-211000503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GNFT","USA","PBC","CCA","GNFTF"],"gpt_icon":0},{"id":"2518789688","title":"GENFIT Secures Bondholder Approval for 2025 OCEANEs Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518789688?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:34","pubTimestamp":1741642497,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Genfit SA ( ($GNFT) ). On March 10, 2025, GENFIT announced the approval of amendments to the terms and conditio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-secures-bondholder-approval-for-2025-oceanes-amendments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-secures-bondholder-approval-for-2025-oceanes-amendments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2518778574","title":"Press Release: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2518778574","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518778574?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:10","pubTimestamp":1741641000,"startTime":"0","endTime":"0","summary":"Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs. -- Closing of Royalty Financing and receipt of first EUR130 million. -- Upon closing of the Royalty Financing, GENFIT will implement the. Repurchase of the 2025 OCEANEs and pay the Consent Fee. The terms and conditions of the 2025 OCEANEs contained a negative pledge clause which limited the ability of the Company to grant security interests to its creditors upon its present or future assets or revenues. The closing of the royalty financing with HCRx , which was signed and announced by GENFIT on January 30, 2025, was subject to approval of 2025 OCEANEs bondholders of an amendment to this negative pledge clause, allowing for the grant of the security interest contemplated in the Royalty Financing documentation, and other customary closing conditions.The result of the vote resolution by resolution is available on the website of the Company .The Company also undertook, s","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","R","GNFTF","CCA","BK4022","GNFT","BK4232","BK4139","PBC"],"gpt_icon":0},{"id":"2516598460","title":"Analysts’ Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516598460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516598460?lang=en_us&edition=fundamental","pubTime":"2025-03-02 09:40","pubTimestamp":1740879606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genfit (GNFTF – Research Report) and Ventyx Bioscien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genfit-gnftf-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genfit-gnftf-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4007","VTYX","BK4139","BK4137","GNFTF"],"gpt_icon":0},{"id":"2514835841","title":"GENFIT Announces Revenues and Cash Position as of December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835841","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835841?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:10","pubTimestamp":1740690600,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents totaled 81.8 million as of December 31, 2024. Revenues amounted to 67.0 million as of December 31, 2024 including the 48.7 million milestone upon first sale of Ipsen’s Iqirvo  in the U.S. for the treatment of Primary Biliary Cholangitis . Lille , Cambridge , Zurich , February 27, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2024 and revenues for 2024. As of December 31, 2024, the Company’s cash and cash equivalents amounted to 81.8 million compared with 77.8 million as of December 31, 2023 and 96.0 million as of September 30, 2024.Of the 67.0 million, 48.7 million was attributable to a milestone payment invoiced to Ipsen in June 2024 and 2.7 million was attributable to royalty revenue from U.S. sales of Iqirvo/elafibranor which commenced mid-June in application of the Ipsen Agreement signed in December 2021. 15.3 milli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-revenues-cash-position-211000393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFTF","GNFT"],"gpt_icon":0},{"id":"2513785685","title":"Kepler Capital  Sticks to Its Buy Rating for Genfit (GNFTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513785685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513785685?lang=en_us&edition=fundamental","pubTime":"2025-02-23 09:37","pubTimestamp":1740274642,"startTime":"0","endTime":"0","summary":"In a report released on February 21, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit (GNFTF – Research Report), with a price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2513878298","title":"GENFIT Advances 2025 OCEANEs Repurchase with Key Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2513878298","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513878298?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:27","pubTimestamp":1740144463,"startTime":"0","endTime":"0","summary":"An update from Genfit SA ( ($GNFT) ) is now available. On February 21, 2025, GENFIT announced the preliminary results of its repurchase offer for 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-advances-2025-oceanes-repurchase-with-key-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-advances-2025-oceanes-repurchase-with-key-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2513305892","title":"Press Release: GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2513305892","media":"Dow Jones","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513305892?lang=en_us&edition=fundamental","pubTime":"2025-02-21 15:30","pubTimestamp":1740123000,"startTime":"0","endTime":"0","summary":"GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting. -- Put Option Agreements signed to date with 2025 OCEANEs holders. -- 2025 OCEANEs holders' general meeting convened for March 10, 2025. Lille , Cambridge , Zurich , February 21, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025.As announced on February 10, 2025 and February 14, 2025, GENFIT has proposed to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally and irrevocably undertake to repurchase the 2025 OCEANEs of such holder, subject to approval by the general meeting of the 2025 OCEANEs holders of the amendment of t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFT","GNFTF","R","BK4022","USA","PBC","CCA","BK4232","BK4139"],"gpt_icon":0},{"id":"2511610727","title":"GENFIT Amends Terms of 2025 OCEANEs Proposal Amid Royalty Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511610727","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511610727?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:27","pubTimestamp":1739568453,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) has shared an update. On February 14, 2025, GENFIT announced amendments to the terms of its dual proposal to the 2025 OCEANEs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-amends-terms-of-2025-oceanes-proposal-amid-royalty-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-amends-terms-of-2025-oceanes-proposal-amid-royalty-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNFTF"],"gpt_icon":0},{"id":"2511683281","title":"Genfit (GNFTF) Gets a Buy from Kepler Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2511683281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511683281?lang=en_us&edition=fundamental","pubTime":"2025-02-14 09:38","pubTimestamp":1739497109,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Justine Telliez maintained a Buy rating on Genfit (GNFTF – Research Report) on February 12 and set a price target of €8.40. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/genfit-gnftf-gets-a-buy-from-kepler-capital-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/genfit-gnftf-gets-a-buy-from-kepler-capital-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNFTF"],"gpt_icon":0},{"id":"2510465858","title":"GENFIT Finalizes 2025 Bond Repurchase Terms Amidst Royalty Financing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510465858","media":"TIPRANKS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510465858?lang=en_us&edition=fundamental","pubTime":"2025-02-10 19:28","pubTimestamp":1739186902,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) has issued an announcement. On February 10, 2025, GENFIT announced the final terms for a dual proposal to its 2025 OCEANEs bo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-finalizes-2025-bond-repurchase-terms-amidst-royalty-financing-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-finalizes-2025-bond-repurchase-terms-amidst-royalty-financing-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","US12M.BOND","BK4139","US3Y.BOND","US6M.BOND","US30Y.BOND","US7Y.BOND","US2Y.BOND","US10Y.BOND","US5Y.BOND"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNFTF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-11-10","symbol":"GNFTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1668056400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-09-28","symbol":"GNFTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1664337600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2022-04-07","symbol":"GNFTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1649304000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNFTF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNFTF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1662868800000}}}